Market Currents
Sucampo Pharmaceuticals (SCMP) -8.4% premarket after announcing Friday the FDA extended by three...
-
Monday, December 3, 2012, 8:42 AM ETSucampo Pharmaceuticals (SCMP) -8.4% premarket after announcing Friday the FDA extended by three months its review of the company's Amitiza drug to treat opioid-induced constipation in patients with chronic, non-cancer pain. The FDA decides to extend the goal date to provide time for a full review of supportive analyses it had requested.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 1 comment:
It's a monthly dividend, and this first one includes 12 days of November (post-IPO) as well as December so forward yield is ~7%. Management is planning on a $0.42 per year payout going forward or $0.035/month after this first, larger one.